- Trial phase
- Approved
- Time to market
- Already approved and marketed (Sunosi, FDA-approved 2019)
- Why 4/10
- Solriamfetol is already FDA-approved and marketed (Sunosi, since 2019), there is no pending PDUFA or pivotal topline readout in the next ~12 months that would trigger a hard binary stock move. The ADHD FOCUS adult trial succeeded but no sNDA has been filed yet; pediatric ADHD trials (FOCUS-2, FOCUS-3) just began dosing. CLARITY (MDD+EDS) is early. Without a dated binary catalyst, the impact score cannot exceed 5 per the rubric.
Solriamfetol is a steady commercial contributor (~$125M FY2025, 32% YoY) with patent protection through 2040, but it is not Axsome's primary growth driver, Auvelity is larger (~$291M in 2024) and just won an Alzheimer's agitation approval. Watch for whether Axsome files an ADHD sNDA in 2H 2026 or 2027, which would create a new regulatory catalyst. Until then, solriamfetol's value is in its reliable cash flow and pipeline-expansion optionality.
Price Chart
Executive Summary
Solriamfetol (Sunosi) is an FDA-approved wakefulness drug for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea, acquired by Axsome from Jazz Pharmaceuticals in 2022. It generated $124.8M in net product revenue in 2025 (up 32% YoY) and $33.9M in Q1 2026 (up 34%). Patent settlements through June 2026 pushed generic entry to 2040, securing long-term exclusivity. The drug is being expanded into four additional Phase 3 indications: adult/pediatric ADHD (FOCUS adult positive March 2025), MDD with EDS (CLARITY started Feb 2026), binge eating disorder, and shift work disorder. The PARADIGM trial in broad MDD failed in April 2025. Axsome's analyst consensus is Strong Buy (25/27 positive) with a mean target of $276.47 (~45% upside), though solriamfetol is a smaller revenue contributor than Axsome's lead drug Auvelity (~$291M in 2024 plus newly approved for Alzheimer's agitation).
How It Works
Solriamfetol is a wakefulness-promoting medication that works by increasing levels of two brain chemicals, dopamine and norepinephrine (by blocking their reuptake), and also activates a receptor called TAAR1. Think of it as a non-stimulant drug that helps people stay awake and alert, similar in concept to caffeine but stronger and targeted. Unlike traditional stimulants, its mechanism is more selective, which may offer a different side-effect profile.
Trial Status
Solriamfetol (brand name Sunosi) is FDA-approved for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea. Three additional Phase 3 trials are in progress or recently completed: (1) FOCUS adult ADHD, positive topline March 2025, sNDA not yet filed; (2) FOCUS-3 (adolescent ADHD), just initiated June 2026; (3) FOCUS-2 (pediatric ADHD), initiated July 2026; (4) CLARITY (MDD with excessive daytime sleepiness), initiated Feb 2026; (5) ENGAGE (binge eating disorder), initiated Apr 2024; (6) SUSTAIN (shift work disorder), initiated Aug 2024. The PARADIGM trial in broad MDD failed its primary endpoint in April 2025 but showed efficacy in the EDS subgroup.
The Two-Sided Case
Upcoming Catalysts
- Potential sNDA submission for adult ADHD (timeline not yet announced, post-FOCUS positive data from March 2025)
- Topline CLARITY Phase 3 data for solriamfetol in MDD with excessive daytime sleepiness (enrollment underway, timeline TBD)
- Topline ENGAGE Phase 3 data for binge eating disorder (enrollment started April 2024)
- Topline SUSTAIN Phase 3 data for shift work disorder (enrollment started August 2024, estimated completion Dec 2026 per clinicaltrials.gov)
- FOCUS-3 (adolescent) and FOCUS-2 (pediatric) ADHD Phase 3 enrollment progress
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Axsome Therapeutics, Inc. Press Release AXSM ·Originating report